ID

26224

Description

Study ID: 101468/125 Clinical Study ID: SKF-101468/125 Study Title: A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Restless Legs Syndrome

Keywords

Versions (1)
  1. 10/12/17 10/12/17 -
Copyright Holder

GlaxoSmithKline

Uploaded on

October 12, 2017

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 Module 1 Concomitant Medication/Adverse Experiences

English

L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 Module 1 Concomitant Medication/Adverse Experiences

1 forms  
Concomitant Medication Information
Description

Concomitant Medication Information

Concomitant Medication Information noticed
Description

Concomitant Medication Information

Data type

boolean

Concomitant Medication
Description

Concomitant Medication

Drug Name (Trade Name Preferred)
Description

Drug Name (Trade Name Preferred)

Data type

text

Total daily dose (e.g. 500 mg)
Description

Total daily dose

Data type

integer

Measurement units
  • mg
mg
Medical Condition
Description

Medical Condition

Data type

text

Approximate Start Date
Description

Approximate Start Date

Data type

date

End Date (leave blank if continuing)
Description

End Date

Data type

date

Continuing
Description

Continuing

Data type

boolean

For SB
Description

For SB

Data type

text

Adverse Experiences
Description

Adverse Experiences

Definition of serious adverse experiences
Description

A serious adverse experience is any experience which is -fatal -life threatening - disabling - incapacitating - results in hospitalization - prolongs a hospital stay - associated with congenital abnormality, carcinoma or overdose

Data type

boolean

Adverse Experience Details
Description

Adverse Experience Details

Experience
Description

Experience

Data type

text

For SB
Description

For SB

Data type

text

Date Started
Description

Date Started

Data type

date

Date Stopped
Description

Date Stopped

Data type

date

Duration (if less than 24hrs)
Description

Duration

Data type

float

Measurement units
  • hrs
hrs
Experience continuing
Description

Experience continuing

Data type

boolean

Course: Continuous
Description

Course

Data type

boolean

If No, no. of episodes
Description

No. of episodes

Data type

integer

Intensity
Description

Intensity

Data type

text

Action taken on Study Medication
Description

Action taken on Study Medication

Data type

integer

Suspected Relationship
Description

Suspected Relationship

Data type

text

Corrective Therapy
Description

Corrective Therapy

Data type

text

Do you consider this a serious adverse experience by the definitions on the tab?
Description

If patient died complete Form D

Data type

integer

Investigator´s Signature
Description

Investigator´s Signature

Investigator´s Signature
Description

Investigator´s Signature

Data type

text

Date
Description

Date

Data type

date

Back to the top of the page

Similar models

L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 Module 1 Concomitant Medication/Adverse Experiences

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Concomitant Medication Information
Concomitant Medication Information
Item
Concomitant Medication Information noticed
boolean
Item Group
Concomitant Medication
Drug Name (Trade Name Preferred)
Item
Drug Name (Trade Name Preferred)
text
Total daily dose
Item
Total daily dose (e.g. 500 mg)
integer
Medical Condition
Item
Medical Condition
text
Approximate Start Date
Item
Approximate Start Date
date
End Date
Item
End Date (leave blank if continuing)
date
Continuing
Item
Continuing
boolean
For SB
Item
For SB
text
Item Group
Adverse Experiences
Definition of serious adverse experiences
Item
Definition of serious adverse experiences
boolean
Item Group
Adverse Experience Details
Experience
Item
Experience
text
For SB
Item
For SB
text
Date Started
Item
Date Started
date
Date Stopped
Item
Date Stopped
date
Duration
Item
Duration (if less than 24hrs)
float
Experience continuing
Item
Experience continuing
boolean
Course
Item
Course: Continuous
boolean
No. of episodes
Item
If No, no. of episodes
integer
Item
Intensity
text
Intensity
Code List
Intensity
CL Item
Mild (1)
CL Item
Moderate (2)
CL Item
Severe (3)
Item
Action taken on Study Medication
integer
Action taken on Study Medication
Code List
Action taken on Study Medication
CL Item
None (1)
CL Item
Dose decreased  (2)
CL Item
Dose increased (3)
CL Item
Drug stopped (4)
CL Item
Dose interrupted (5)
Item
Suspected Relationship
text
Suspected Relationship
Code List
Suspected Relationship
CL Item
Related (1)
CL Item
Possibly related (2)
CL Item
Probably unrelated  (3)
CL Item
Unrelated (4)
Item
Corrective Therapy
text
Corrective Therapy
Code List
Corrective Therapy
CL Item
Yes (If "Yes" record on Medication form) (1)
CL Item
No (2)
Item
Do you consider this a serious adverse experience by the definitions on the tab?
integer
Serious Adverse Experience by Definition
Code List
Do you consider this a serious adverse experience by the definitions on the tab?
CL Item
Yes (If "Yes", report to SB by telephone within 24 hours) (1)
CL Item
No (2)
Item Group
Investigator´s Signature
Investigator´s Signature
Item
Investigator´s Signature
text
Date
Item
Date
date
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial